CONMED Corporation (CNMD) Fair Value 2026

CNMD · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.5 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, CONMED Corporation (CNMD) trades at $50.32, versus a $51.17 median fair value across its 12 active models — 1.7% above the current price. QOC: 8.5/10. Value Trap Risk: 0/100 (SAFE). 12/13 models active. Within that set, the Bayesian DCF component alone returns $85.19.

Key Facts

Ticker
CNMD
Price
$50.32
Quality Score
8.5/10
Value Trap Risk
0/100
Models Active
12/13
Last Updated
Strength: Bayesian DCF suggests +69.3% upside with 73% confidence
Risk: Limited model coverage (12/13) may reduce confidence

Is CONMED Corporation (CNMD) Undervalued or Overvalued in 2026?

According to CirclFi’s 12-model valuation engine, CONMED Corporation (CNMD) appears fairly valued as of : the median of 12 independent fair value estimates is $51.17, within 1.7% of the current price of $50.32. Estimates range from $6.94 to $86.82. CNMD scores 8.5/10 on fundamental quality and 0/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. CNMD’s +1.7% gap is narrower than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy CONMED Corporation Stock in 2026? →

What Fair Value Does Each Model Give CNMD?

12 Intrinsic Value Models vs. Current Price ($50.32)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $85.19 +69.3%
Intrinsic · High Conviction
 $8.47 -83.2%
Ensemble · Low Conviction
 $44.15 -12.3%
Scenario · High Conviction
 $62.06 +23.3%
Unlock the Full Matrix

Access 8 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is CNMD's Fair Value Range?

Spread across 12 independent models · $6.94 to $86.82

CirclFi's 12 active models place CONMED Corporation (CNMD) between $6.94 and $86.82 per share, a spread of 156% of the median. The median of that range — $51.17 — is the fair value CirclFi publishes for CNMD, against a current price of $50.32.

Low · Markov DDMHigh · Regime Cross
$6.94median $51.17$86.82
Where the range comes from
Most bearish modelMarkov DDM$6.94
Most bullish modelRegime Cross-Sectional$86.82
Model agreement6 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CNMD. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CNMD, not a CirclFi price target. How each model works →

What Is CONMED Corporation (CNMD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, CONMED Corporation presents a highly debated valuation profile at its current price of $50.32. The median intrinsic value is estimated at $51.17 (+1.7% median upside), masking a wide model spread between the 6 bullish models and 6 bearish models. Model dispersion is worth noting: Regime Cross targets $86.82 (+72.5%), versus Markov DDM at $6.94 (-86.2%). This +158.7% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About CNMD?

12 of 13 models are currently active for CNMD. Of these, 6 models suggest upside while 6 models suggest overvaluation. Taken together, their median fair value for CNMD is $51.17 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $85.19 on its own, implying +69.3% upside from the current price. See which stocks rank higher →

How Does CNMD Rank in Medical Devices?

Among 157 Medical Devices stocks, CNMD ranks #18 by Quality of Company score. CirclFi's QOC score of 8.5/10 evaluates 32 fundamental signals. A score of 8.5 places CNMD in the top tier.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to biopharma enterprise businesses. For CONMED Corporation, metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.

Is CNMD a Value Trap?

CirclFi's Value Trap algorithm assigns CNMD a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for CONMED Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, CONMED Corporation scores 8.5 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +158.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CNMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CNMD's 12 active models, average confidence is 55%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy CONMED Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

INMDInMode Ltd.QOC 8.5XTNTXtant Medical Holdings, Inc.QOC 8.4SNNSmith & Nephew plcQOC 8.7ZBHZimmer Biomet Holdings, Inc.QOC 8.4EWEdwards Lifesciences CorporationQOC 8.7HAEHaemonetics CorporationQOC 8.3SENSSenseonics Holdings, Inc.QOC 6.8QDELQuidelOrtho CorporationQOC 5.8POASPhaos Technology Holdings (CaymQOC 4.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: INMD · XTNT · SNN · ZBH · EW · HAE · SENS · QDEL · POAS · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to CNMD?

7 companies across all industries closest to CNMD’s Quality of Company score of 8.5/10.

HRBH&R Block, Inc.QOC 8.5GSKGSK plcQOC 8.5PKGPackaging Corporation of AmericaQOC 8.5VASOVaso CorporationQOC 8.5HAFNHafnia LimitedQOC 8.5WDLFDecentral Life, Inc.QOC 8.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HRB · GSK · PKG · VASO · HAFN · WDLF · NVDA

Where Does CNMD Sit in CirclFi's Medical Devices Rankings?

CNMD is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About CONMED Corporation’s Valuation?

What is CONMED Corporation's intrinsic value in 2026?

CirclFi puts CONMED Corporation (CNMD)'s intrinsic value at $51.17 — the median of 12 independent model estimates as of 2026-08-27, ranging from $6.94 to $86.82. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $85.19 on its own. The Quality of Company score is 8.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CNMD overvalued or undervalued right now?

At $50.32, 6 of 12 active models suggest CNMD may be undervalued, while 6 indicate potential overvaluation. The median of all 12 fair value estimates is $51.17, within 1.7% of the current price of $50.32 — a consensus view that CNMD is fairly valued. The assessment depends on which methodology best fits CONMED Corporation's business model in Medical Devices.

What does a Quality of Company score of 8.5 mean for CNMD?

CONMED Corporation's QOC of 8.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on CNMD?

CirclFi analyzes CNMD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CNMD?

Of the 12 models currently active on CNMD, Regime Cross-Sectional is the most bullish at $86.82 per share, and Markov DDM is the most bearish at $6.94. CirclFi's published fair value for CNMD is the median of that range, $51.17, not either extreme. The gap between the two ends equals 156% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CNMD a value trap in 2026?

CONMED Corporation's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 12-model valuation engine, CONMED Corporation (CNMD) has a median fair value of $51.17 — within 1.7% of the current price of $50.32 — as of 2026-08-27.” Source: circlfi.com/stock/CNMD/ · Methodology
Primary sources for this CNMD valuation
  • Financial statements: CONMED Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000816956) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CNMD as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on CNMD.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

8 models hidden for CNMD Unlock All 12 — $39/mo